Characterization and analysis of the aggregation of a single-chain chimeric anti-ErbB2 antibody.
- Author:
Juanjuan ZHU
1
;
Ziye RONG
;
Bing JIANG
;
Jing LIU
Author Information
1. School of Life Sciences, University of Science and Technology of China, Hefei 230027, China.
- Publication Type:Journal Article
- MeSH:
Antibodies;
chemistry;
metabolism;
Humans;
Immunoglobulin Fc Fragments;
chemistry;
metabolism;
Immunoglobulin Variable Region;
chemistry;
metabolism;
Protein Conformation;
Protein Engineering;
methods;
Receptor Aggregation;
immunology;
Receptor, ErbB-2;
chemistry;
immunology;
Recombinant Proteins;
biosynthesis;
chemistry;
genetics;
immunology
- From:
Chinese Journal of Biotechnology
2008;24(11):1918-1923
- CountryChina
- Language:Chinese
-
Abstract:
We studied the aggregation of a recombinant engineering antibody (chA21). Anti-ErbB2 antibody chA21 was produced by fusing single-chain Fv (scFv) with human IgG1 Fc fragment, and it was proved to be a drug candidate for cancer therapy. We characterized the aggregation of chA21 by high performance sized-exclusive chromatography (HPSEC), dynamic light scattering (DLS), SDS-PAGE, indirect ELISA assay, and compared the influence of temperature and additive on the level of aggregation and binding activity. Conformation changes of different levels of aggregation were also analyzed via circular dichroism (CD). Finally, we analyzed which part of chA21 was involved in aggregation by cleaving it into scFv and Fc fragments. The results showed that chA21 could form aggregates in the storage solution. The aggregates interacted through non-covalent bonds and remained binding activity. Temperature and additive could slightly affect the level of aggregation and binding activity, while the conformations of chA21 were stable. Aggregation propensity of scFv fragment was almost same as chA21, indicating that scFv may be the major part to form the aggregates. The research on aggregation may be helpful to develop a suitable formulation for chA21 clinical application as well as provide direction for future antibody design and reconstruction.
